You do not need to guess what a problematic GLP-1 provider looks like. Regulators have published what they object to, and the same patterns appear again and again. This is a checklist built from those cases rather than from general suspicion.
What regulators have done
Two strands of enforcement matter here. The FDA has issued waves of warning letters to telehealth companies over misleading marketing of compounded GLP-1 products, reported at 58 firms in September 2025 and around 30 more in March 2026. Separately, the Federal Trade Commission took action against telehealth provider NextMed in 2025 over advertising practices, with a settlement requiring full cost transparency before payment.
Those cases are useful precisely because they are specific. They tell you which claims crossed a line, which lets you evaluate any provider against the same standard.
Red flag 1: claiming compounded medication is the same as the brand
This is the central issue in the FDA letters. A compounded preparation containing semaglutide is not Ozempic or Wegovy, is not a generic of either, and has not been evaluated by the FDA for safety, effectiveness or quality. Marketing that describes it as the same as, equivalent to, or a generic version of a branded product is what regulators have acted on.
Good practice looks like the disclaimers on Coby Health, which state on every product mention that the compounded medication is not FDA-approved, is not a generic form of the branded product, and that the company has no affiliation with Novo Nordisk or Eli Lilly. REMEVi and Cora Health carry equivalent language.
Red flag 2: prices that exclude the medication
The FTC action against NextMed concerned advertising monthly prices that excluded the medication cost, lab work and provider consultations. The settlement required full cost transparency before payment. This remains the most common pricing tactic in the category.
- A headline price that turns out to be a membership fee with medication billed separately
- A starting-dose price presented as the monthly cost, with the price rising as you titrate
- An advertised rate available only on a six or twelve-month prepayment, shown as though it were monthly
- Labs, supplies or shipping excluded from a price described as all-inclusive
- A promotional rate with a countdown timer and an undisclosed renewal price
- A final checkout total that differs from the landing page figure
Our guides to providers with no membership fee and flat-rate pricing work through which providers avoid each of these.
Red flag 3: no named compounding pharmacy
If a provider will not tell you which pharmacy prepares your medication, you cannot check its licence, its accreditation, or its FDA inspection history. That is the whole of your ability to verify anything about a product the FDA has not reviewed.
By one industry estimate only 15 to 20 percent of US GLP-1 telehealth providers name a pharmacy publicly. Our guide to which providers name their compounding pharmacy tracks who does.
Red flag 4: a prescription promised before evaluation
Any provider that implies you will receive medication before a licensed clinician has reviewed your health profile is not describing legitimate medical practice. Look for the opposite language: Coby Health states that payment does not guarantee the issuance or dispensing of prescriptions, and Trinity Meds states that a prescription is never guaranteed and remains at provider discretion.
Paying before the consultation is not automatically a red flag
Several legitimate providers, including Embody, take payment before the clinician consultation. What matters is whether they are clear that a prescription may not follow, and whether you get a refund if it does not. SkinnyVIP handles this best by stating you only pay if a clinician approves treatment.
Red flag 5: fabricated or manipulated reviews
The FTC specifically targeted NextMed over posting fake customer reviews and incentivising the removal of negative ones. Signals worth noticing include a wall of five-star testimonials with no verifiable source, review counts that jump abruptly, and testimonials attributed only to first names with stock imagery.
Better practice looks like citing a third-party platform you can check independently, and disclosing when imagery features models rather than patients. REMEVi does both, stating that its homepage hero features a model and that its star ratings are live averages from its public Google and Trustpilot profiles.
Red flag 6: trial results presented as the provider's own
STEP 1 reported roughly 14.9 percent mean weight loss with FDA-approved semaglutide, and SURMOUNT-1 roughly 20.9 to 22.5 percent with FDA-approved tirzepatide. Those figures belong to the branded products studied. A compounded preparation has not been studied at that scale, and presenting trial percentages as what the provider's patients achieve conflates the two.
Providers handling this correctly label the source explicitly. Trinity Meds states that its results reflect self-reported member data and are not derived from clinical trials or peer-reviewed studies, which is exactly the right distinction to draw.
Red flag 7: no way to check what you are being told
The pattern connecting most of the above is unverifiability. Every item on the following list is something a provider can publish at no cost, and the absence of several together is more telling than any single gap.
| What to look for | Why it matters | Example of good practice |
|---|---|---|
| Named compounding pharmacy | The only independently checkable fact about a compounded product | Cora Health, Ondra Health, REMEVi, AltRx |
| Named prescribing practice | Lets you verify the clinician in the NPPES registry | Cora and Ondra both name Wasef Health, PC |
| Full price ladder | Shows what happens at renewal and at other commitment lengths | Cora, Ondra and REMEVi publish every term |
| Published refund policy | Determines what happens to a prepayment if you stop | Cora publishes a detailed calculation |
| Batch testing available | Confirms potency, sterility and endotoxin testing was done | REMEVi provides lot documentation on request |
| Third-party certification | LegitScript, PCAB or NABP can be checked directly | Cora, Ondra, REMEVi, Hallandale, Belmar |
What is not a red flag
A few things that look alarming but usually are not. Asynchronous consultation is legal in many states and is how a large share of legitimate telehealth operates. A platform that says it does not itself prescribe is describing a normal corporate structure, not evading responsibility. Compounded medication itself is lawful when prepared by a licensed pharmacy against a valid prescription. And a small operation is not inherently worse than a venture-backed one.
Judge providers on disclosure, pricing honesty and clinical process rather than on size or business model. For the wider trade-off between compounded and FDA-approved routes, see brand-name versus compounded GLP-1 medications.
Frequently Asked Questions
What have regulators actually flagged about GLP-1 telehealth?
The FDA has issued waves of warning letters over misleading marketing of compounded GLP-1 products, reported at 58 firms in September 2025 and around 30 more in March 2026. The FTC took action against NextMed in 2025 over advertising that excluded medication, lab and consultation costs, and over fabricated reviews.
Is compounded semaglutide illegal?
No. Compounding is lawful when performed by a licensed pharmacy against a valid patient-specific prescription. What regulators have acted on is marketing that presents compounded preparations as equivalent to FDA-approved products, and pricing that hides costs.
Is it a red flag if I pay before speaking to a clinician?
Not by itself. Several legitimate providers take payment first. What matters is whether they state clearly that a prescription is not guaranteed, and whether you are refunded if a clinician declines to prescribe.
How do I check a provider's compounding pharmacy?
Ask for the name, then look up its state board of pharmacy licence, check PCAB or NABP accreditation with those bodies directly, and search the FDA's public compounding facility inspection and enforcement records.
Are asynchronous consultations a warning sign?
No. Asynchronous review is permitted in many states and is how much legitimate telehealth operates. The question worth asking is what happens next: whether a clinician reviews your case individually and whether follow-up is available.
What is the single most useful check?
Whether the provider names its compounding pharmacy. It costs nothing to publish, it is independently verifiable, and providers that publish it tend also to publish fuller pricing and clearer refund terms.
Should trial weight-loss figures make me confident?
Only about the medication studied. STEP 1 and SURMOUNT-1 tested FDA-approved branded products. A compounded preparation has not been studied at that scale, so those percentages should never be presented as what a compounded programme delivers.
Medical Disclaimer
This article is for general information only and is not medical advice, a diagnosis, or a treatment recommendation. GLP-1 medications are prescription drugs with real risks and contraindications. Only a licensed clinician who knows your history can decide whether any medication is appropriate for you. Pricing, programmes and policies described here reflect what providers published at the time of writing and change frequently; verify everything directly before enrolling. See our full medical disclaimer.